NCT07397728
" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Trial completed
- Final enrollment: 180 participants (planned 90)
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Systemic Lupus Erythematosus Assessment
Timeframe: 3 Months
TREX1 gene polymorphism and SLE
Timeframe: 3 Months
Arms and interventions
Group A : (Systemic Lupus Erythrematosus)
About 90 patients diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation.
Group B (Healthy Controls)
90 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA.
Diagnostic tests: TREX1 gene polymorphisms
Sites
1 site in 1 country
- Qina University hospital, South Valley University HospitalQina, South Valley, Egypt